Gritstone Bio EPS - Earnings per Share 2017-2024 | GRTSQ
Gritstone Bio Annual EPS | |
---|---|
2023 | $-1.20 |
2022 | $-1.32 |
2021 | $-0.95 |
2020 | $-2.79 |
2019 | $-2.81 |
2018 | $-7.26 |
2017 | $-20.70 |
2016 | $-11.21 |
Gritstone Bio Quarterly EPS | |
---|---|
2024-06-30 | $-0.16 |
2024-03-31 | $-0.34 |
2023-12-31 | $-0.26 |
2023-09-30 | $-0.33 |
2023-06-30 | $-0.31 |
2023-03-31 | $-0.30 |
2022-12-31 | $-0.29 |
2022-09-30 | $-0.35 |
2022-06-30 | $-0.34 |
2022-03-31 | $-0.34 |
2021-12-31 | $-0.36 |
2021-09-30 | $-0.36 |
2021-06-30 | $-0.33 |
2021-03-31 | $0.10 |
2020-12-31 | $-0.70 |
2020-09-30 | $-0.69 |
2020-06-30 | $-0.69 |
2020-03-31 | $-0.71 |
2019-12-31 | $-0.79 |
2019-09-30 | $-0.77 |
2019-06-30 | $-0.63 |
2019-03-31 | $-0.62 |
2018-12-31 | $12.94 |
2018-09-30 | $-7.60 |
2018-06-30 | $-6.57 |
2018-03-31 | $-6.03 |
2017-12-31 | $0.00 |
2017-09-30 | $-4.59 |
2016-12-31 | $0.00 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | MED-BIOMED/GENE | $0.000B | $0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Top KingWin (WAI) | China | $0.007B | 0.00 |
S&W Seed (SANW) | United States | $0.007B | 0.00 |
Invo BioScience (NAYA) | United States | $0.004B | 0.00 |